Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson's Disease

Author's Avatar
Nov 08, 2018
Article's Main Image

One-time treatment with VY-AADC demonstrates durable improvements in motor function at 18 months and beyond from ongoing Phase 1b trial